SCHEMBL6726546

SCHEMBL6726546

O=C(O)NC(C(=O)Nc1ccc(OC(F)(F)F)cc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.55
MAPT P10636 2/20 0.55
TP53 P04637 1/20 0.55
FPR2 P25090 1/20 0.53
ACHE P22303 1/20 0.52
KMT2A Q03164 1/20 0.50
MMP12 P39900 2/20 0.48
MMP13 P45452 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
FAAH O00519 1/20 0.48
F9 P00740 1/20 0.47
THRB P10828 1/20 0.47
IGF1R P08069 1/20 0.47
STING1 Q86WV6 1/20 0.47
HPGD P15428 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TRPV1 Q8NER1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8336006 0.85 CTSS (0.56) EPHX2MAPTTP53FPR2ACHE
SCHEMBL6720054 0.83 RAB9A (0.55) EPHX2MAPTTP53FPR2KMT2A
SCHEMBL6715920 0.82 POLB (0.61) EPHX2MAPTTP53FPR2KMT2A
SCHEMBL6719574 0.82 EPHX2 (0.56) EPHX2MAPTTP53FPR2ACHE
SCHEMBL6715776 0.82 KLK7 (0.61) MAPTKMT2ACYP1A2CYP2C19ALDH1A1
SCHEMBL6718828 0.80 ALDH1A1 (0.61) MAPTKMT2AALDH1A1
SCHEMBL6715725 0.79 MEN1 (0.54) KMT2AALDH1A1
SCHEMBL16563805 0.79 EPHX1 (0.48) EPHX2FPR2KMT2AMMP12MMP13
SCHEMBL2096312 0.77 EPHX2 (0.76) EPHX2MAPTKMT2ACYP1A2CYP2C19
SCHEMBL6716780 0.77 CRHBP (0.61) MAPTTP53KMT2ACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 EPHX2 1910/4885MAPT 694/4885TP53 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.